Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
CREDENCE
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
3 other identifiers
interventional
4,401
34 countries
575
Brief Summary
The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 diabetes-mellitus-type-2
Started Feb 2014
Longer than P75 for phase_3 diabetes-mellitus-type-2
575 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 17, 2014
CompletedStudy Start
First participant enrolled
February 17, 2014
CompletedFirst Posted
Study publicly available on registry
February 19, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2018
CompletedResults Posted
Study results publicly available
November 20, 2019
CompletedDecember 5, 2019
December 1, 2019
4.7 years
February 17, 2014
October 30, 2019
December 4, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death
Primary composite endpoint is the composite of DoSC, ESKD, and renal or CV death. DoSC: from baseline average determination (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). ESKD: as initiation of maintenance dialysis for at least 30 days, or renal transplantation, or an estimated glomerular filtration rate (eGFR) value of less than (\<)15 milliliters per minute per 1.73 square meter (mL/min/1.73 m\^2) (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). Renal death: death in participants who had reached ESKD, died without initiating renal replacement therapy, and no other cause of death was determined via adjudication. Adjudication of these events by Endpoint Adjudication Committee (EAC) was performed in blinded fashion. Event rate estimated based on time to first occurrence of primary composite endpoint are presented.
Up to 4.6 years
Secondary Outcomes (7)
Composite Endpoint of CV Death and Hospitalized Heart Failure (HHF)
Up to 4.6 years
Major Adverse Cardiac Event (MACE)
Up to 4.6 years
Hospitalized Heart Failure (HHF)
Up to 4.6 years
Renal Composite Endpoint
Up to 4.6 years
Cardiovascular (CV) Death
Up to 4.6 years
- +2 more secondary outcomes
Study Arms (2)
Canagliflozin 100 mg
EXPERIMENTALEach participant will receive 100 mg of canagliflozin once daily
Placebo
PLACEBO COMPARATOREach participant will receive matching placebo once daily
Interventions
Eligibility Criteria
You may qualify if:
- Type 2 diabetes mellitus with a hemoglobin A1c (HbA1c) greater than or equal to (\>=) 6.5 percent (%) and less than or equal to (\<=) 12.0%, with an estimated glomerular filtration rate (eGFR) of \>= 30 milliliter (mL)/minute (min)/1.73meter (m)\^2 and less than (\<) 90 mL/min/1.73 m\^2
- Participants need to be on a stable maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 4 weeks prior to randomization
- Must have a urine albumin to creatinine ratio (UACR) of greater than (\>) 300 milligram (mg)/gram (g) and \<= 5000 mg/g
You may not qualify if:
- History of diabetic ketoacidosis or type 1 diabetes mellitus
- History of hereditary glucose-galactose malabsorption or primary renal glucosuria
- Renal disease that required treatment with immunosuppressive therapy
- Known significant liver disease
- Current or history of New York Heart Association (NYHA) Class IV heart failure
- Blood potassium level \>5.5 millimole (mmol)/liter (L) during Screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (575)
Unknown Facility
Birmingham, Alabama, United States
Unknown Facility
Montgomery, Alabama, United States
Unknown Facility
Tempe, Arizona, United States
Unknown Facility
Tucson, Arizona, United States
Unknown Facility
Little Rock, Arkansas, United States
Unknown Facility
Sherwood, Arkansas, United States
Unknown Facility
Bakersfield, California, United States
Unknown Facility
Chula Vista, California, United States
Unknown Facility
Covina, California, United States
Unknown Facility
Downey, California, United States
Unknown Facility
Fountain Valley, California, United States
Unknown Facility
Hawthorne, California, United States
Unknown Facility
Inglewood, California, United States
Unknown Facility
Laguna Hills, California, United States
Unknown Facility
Lakewood, California, United States
Unknown Facility
Long Beach, California, United States
Unknown Facility
Los Angeles, California, United States
Unknown Facility
Lynwood, California, United States
Unknown Facility
Northridge, California, United States
Unknown Facility
Oakland, California, United States
Unknown Facility
Orange, California, United States
Unknown Facility
Pasadena, California, United States
Unknown Facility
Roseville, California, United States
Unknown Facility
Sacramento, California, United States
Unknown Facility
Salinas, California, United States
Unknown Facility
San Diego, California, United States
Unknown Facility
San Dimas, California, United States
Unknown Facility
Stanford, California, United States
Unknown Facility
Tustin, California, United States
Unknown Facility
Whittier, California, United States
Unknown Facility
Denver, Colorado, United States
Unknown Facility
Golden, Colorado, United States
Unknown Facility
Lakewood, Colorado, United States
Unknown Facility
Washington, Colorado, United States
Unknown Facility
Washington D.C., District of Columbia, United States
Unknown Facility
Coral Springs, Florida, United States
Unknown Facility
Doral, Florida, United States
Unknown Facility
Hialeah, Florida, United States
Unknown Facility
Jacksonville, Florida, United States
Unknown Facility
Miami, Florida, United States
Unknown Facility
Miami Springs, Florida, United States
Unknown Facility
North Miami Beach, Florida, United States
Unknown Facility
Ocala, Florida, United States
Unknown Facility
Port Charlotte, Florida, United States
Unknown Facility
St. Petersburg, Florida, United States
Unknown Facility
Winter Park, Florida, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Augusta, Georgia, United States
Unknown Facility
Columbus, Georgia, United States
Unknown Facility
Roswell, Georgia, United States
Unknown Facility
Snellville, Georgia, United States
Unknown Facility
Stockbridge, Georgia, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Crystal Lake, Illinois, United States
Unknown Facility
Gurnee, Illinois, United States
Unknown Facility
Mount Prospect, Illinois, United States
Unknown Facility
Winfield, Illinois, United States
Unknown Facility
Fort Wayne, Indiana, United States
Unknown Facility
Indianapolis, Indiana, United States
Unknown Facility
Merrillville, Indiana, United States
Unknown Facility
Michigan City, Indiana, United States
Unknown Facility
Muncie, Indiana, United States
Unknown Facility
Council Bluffs, Iowa, United States
Unknown Facility
Louisville, Kentucky, United States
Unknown Facility
Paducah, Kentucky, United States
Unknown Facility
Kenner, Louisiana, United States
Unknown Facility
Rockport, Maine, United States
Unknown Facility
Scarborough, Maine, United States
Unknown Facility
Annapolis, Maryland, United States
Unknown Facility
Baltimore, Maryland, United States
Unknown Facility
Beltsville, Maryland, United States
Unknown Facility
Hyattsville, Maryland, United States
Unknown Facility
Silver Spring, Maryland, United States
Unknown Facility
Boston, Massachusetts, United States
Unknown Facility
Plymouth, Massachusetts, United States
Unknown Facility
Springfield, Massachusetts, United States
Unknown Facility
Worcester, Massachusetts, United States
Unknown Facility
Flint, Michigan, United States
Unknown Facility
Jackson, Mississippi, United States
Unknown Facility
Chesterfield, Missouri, United States
Unknown Facility
Kansas City, Missouri, United States
Unknown Facility
St Louis, Missouri, United States
Unknown Facility
Fremont, Nebraska, United States
Unknown Facility
Lincoln, Nebraska, United States
Unknown Facility
Omaha, Nebraska, United States
Unknown Facility
Reno, Nebraska, United States
Unknown Facility
Las Vegas, Nevada, United States
Unknown Facility
Eatontown, New Jersey, United States
Unknown Facility
Albuquerque, New Mexico, United States
Unknown Facility
Albany, New York, United States
Unknown Facility
Binghamton, New York, United States
Unknown Facility
Buffalo, New York, United States
Unknown Facility
Great Neck, New York, United States
Unknown Facility
Lake Success, New York, United States
Unknown Facility
New Hyde Park, New York, United States
Unknown Facility
New York, New York, United States
Unknown Facility
Ridgewood, New York, United States
Unknown Facility
Riverhead, New York, United States
Unknown Facility
Smithtown, New York, United States
Unknown Facility
Springfield Gardens, New York, United States
Unknown Facility
Asheville, North Carolina, United States
Unknown Facility
Calabash, North Carolina, United States
Unknown Facility
Charlotte, North Carolina, United States
Unknown Facility
Durham, North Carolina, United States
Unknown Facility
Greensboro, North Carolina, United States
Unknown Facility
Greenville, North Carolina, United States
Unknown Facility
High Point, North Carolina, United States
Unknown Facility
Morehead City, North Carolina, United States
Unknown Facility
Morganton, North Carolina, United States
Unknown Facility
Raleigh, North Carolina, United States
Unknown Facility
Tabor City, North Carolina, United States
Unknown Facility
Whiteville, North Carolina, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Columbus, Ohio, United States
Unknown Facility
Maumee, Ohio, United States
Unknown Facility
Roseburg, Oregon, United States
Unknown Facility
Beaver, Pennsylvania, United States
Unknown Facility
Bethlehem, Pennsylvania, United States
Unknown Facility
Philadelphia, Pennsylvania, United States
Unknown Facility
Pittsburgh, Pennsylvania, United States
Unknown Facility
Anderson, South Carolina, United States
Unknown Facility
Columbia, South Carolina, United States
Unknown Facility
Lancaster, South Carolina, United States
Unknown Facility
Murrells Inlet, South Carolina, United States
Unknown Facility
Orangeburg, South Carolina, United States
Unknown Facility
Sumter, South Carolina, United States
Unknown Facility
Chattanooga, Tennessee, United States
Unknown Facility
Knoxville, Tennessee, United States
Unknown Facility
Memphis, Tennessee, United States
Unknown Facility
Arlington, Texas, United States
Unknown Facility
Corpus Christi, Texas, United States
Unknown Facility
Corsicana, Texas, United States
Unknown Facility
Dallas, Texas, United States
Unknown Facility
Edinburg, Texas, United States
Unknown Facility
Fort Worth, Texas, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
Mesquite, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Schertz, Texas, United States
Unknown Facility
Sugar Land, Texas, United States
Unknown Facility
Temple, Texas, United States
Unknown Facility
Waco, Texas, United States
Unknown Facility
Salt Lake City, Utah, United States
Unknown Facility
Bennington, Vermont, United States
Unknown Facility
Burlington, Vermont, United States
Unknown Facility
Bluefield, Virginia, United States
Unknown Facility
Mechanicsville, Virginia, United States
Unknown Facility
Norfolk, Virginia, United States
Unknown Facility
Suffolk, Virginia, United States
Unknown Facility
Spokane, Washington, United States
Unknown Facility
Huntington, West Virginia, United States
Unknown Facility
Milwaukee, Wisconsin, United States
Unknown Facility
Bahía Blanca, Argentina
Unknown Facility
Buenos Aires, Argentina
Unknown Facility
Ciudad Autonoma Buenos Aires, Argentina
Unknown Facility
Corrientes, Argentina
Unknown Facility
Córdoba, Argentina
Unknown Facility
Godoy Cruz, Argentina
Unknown Facility
Junín, Argentina
Unknown Facility
La Plata, Argentina
Unknown Facility
La Plata Lpl Lpl, Argentina
Unknown Facility
Mar del Plata, Argentina
Unknown Facility
Mendoza, Argentina
Unknown Facility
Morón, Argentina
Unknown Facility
Munro, Argentina
Unknown Facility
Paraná, Argentina
Unknown Facility
Quilmes, Argentina
Unknown Facility
Ramos Mejía, Argentina
Unknown Facility
Rosario, Argentina
Unknown Facility
Salta, Argentina
Unknown Facility
San Luis, Argentina
Unknown Facility
San Martín, Argentina
Unknown Facility
San Migeul de Tucuman, Argentina
Unknown Facility
San Miguel de Tucumán, Argentina
Unknown Facility
San Nicolás, Argentina
Unknown Facility
Santa Fe, Argentina
Unknown Facility
Sarandí, Argentina
Unknown Facility
Tapiales, Argentina
Unknown Facility
Temperley, Argentina
Unknown Facility
Villa María, Argentina
Unknown Facility
Zarate, Buenos Aires, Argentina
Unknown Facility
Cairns, Australia
Unknown Facility
Concord, Australia
Unknown Facility
Darlinghurst, Australia
Unknown Facility
Elizabeth Vale, Australia
Unknown Facility
Fremantle, Australia
Unknown Facility
Gosford, Australia
Unknown Facility
Heidelberg, Australia
Unknown Facility
Keswick, Australia
Unknown Facility
Meadowbrook, Australia
Unknown Facility
Parkville, Australia
Unknown Facility
Reservoir, Australia
Unknown Facility
Richmond, Australia
Unknown Facility
St Albans, Australia
Unknown Facility
St Leonards, Australia
Unknown Facility
Sydney, Australia
Unknown Facility
Woolloongabba, Australia
Unknown Facility
Aparecida de Goiânia, Brazil
Unknown Facility
Belém, Brazil
Unknown Facility
Belo Horizonte, Brazil
Unknown Facility
Botucatu, Brazil
Unknown Facility
Brasília, Brazil
Unknown Facility
Campina Grande do Sul, Brazil
Unknown Facility
Campinas, Brazil
Unknown Facility
Canoas, Brazil
Unknown Facility
Caxias do Sul, Brazil
Unknown Facility
Curitiba, Brazil
Unknown Facility
Fortaleza, Brazil
Unknown Facility
Joinville, Brazil
Unknown Facility
Juiz de Fora, Brazil
Unknown Facility
Maringá, Brazil
Unknown Facility
Passo Fundo, Brazil
Unknown Facility
Porto Alegre, Brazil
Unknown Facility
Rio de Janeiro, Brazil
Unknown Facility
Santo André, Brazil
Unknown Facility
São José do Rio Preto, Brazil
Unknown Facility
São José dos Campos, Brazil
Unknown Facility
São Paulo, Brazil
Unknown Facility
Tatuí, Brazil
Unknown Facility
Blagoevgrad, Bulgaria
Unknown Facility
Byala, Bulgaria
Unknown Facility
Golenci, Bulgaria
Unknown Facility
Pazardzhik, Bulgaria
Unknown Facility
Pleven, Bulgaria
Unknown Facility
Plovdiv, Bulgaria
Unknown Facility
Sofia, Bulgaria
Unknown Facility
Varna, Bulgaria
Unknown Facility
Edmonton, Alberta, Canada
Unknown Facility
New Westminster, British Columbia, Canada
Unknown Facility
Vancouver, British Columbia, Canada
Unknown Facility
Winnipeg, Manitoba, Canada
Unknown Facility
Brampton, Ontario, Canada
Unknown Facility
London, Ontario, Canada
Unknown Facility
Newmarket, Ontario, Canada
Unknown Facility
Oshawa, Ontario, Canada
Unknown Facility
Smiths Falls, Ontario, Canada
Unknown Facility
Thornhill, Ontario, Canada
Unknown Facility
Toronto, Ontario, Canada
Unknown Facility
Weston, Ontario, Canada
Unknown Facility
Greenfield Park, Quebec, Canada
Unknown Facility
Montreal, Quebec, Canada
Unknown Facility
Québec, Quebec, Canada
Unknown Facility
Québec, Canada
Unknown Facility
Toronto, Canada
Unknown Facility
Vancouver, Canada
Unknown Facility
Concepción, Chile
Unknown Facility
Santiago, Chile
Unknown Facility
Temuco, Chile
Unknown Facility
Beijing, China
Unknown Facility
Changchun, China
Unknown Facility
Changde, China
Unknown Facility
Changsha, China
Unknown Facility
Chengdu, China
Unknown Facility
Chenzhou, China
Unknown Facility
Dalian, China
Unknown Facility
Foshan, China
Unknown Facility
Guangzhou, China
Unknown Facility
Huai'an, China
Unknown Facility
Nanchang, China
Unknown Facility
Nanjing, China
Unknown Facility
Shanghai, China
Unknown Facility
Shenyang, China
Unknown Facility
Ürümqi, China
Unknown Facility
Wuhan, China
Unknown Facility
Xi'an, China
Unknown Facility
Barranquilla, Colombia
Unknown Facility
Bogotá, Colombia
Unknown Facility
Bucaramanga, Colombia
Unknown Facility
Cali, Colombia
Unknown Facility
Floridablanca, Colombia
Unknown Facility
Manizales, Colombia
Unknown Facility
Medellín, Colombia
Unknown Facility
Pasto, Colombia
Unknown Facility
Pereira, Colombia
Unknown Facility
Choceň, Czechia
Unknown Facility
České Budějovice, Czechia
Unknown Facility
Český Krumlov, Czechia
Unknown Facility
Havlíčkův Brod, Czechia
Unknown Facility
Hradec Kralove-Vekose, Czechia
Unknown Facility
Hradec nad Svitavou, Czechia
Unknown Facility
Jindřichův Hradec, Czechia
Unknown Facility
Olomouc, Czechia
Unknown Facility
Prague, Czechia
Unknown Facility
Slaný, Czechia
Unknown Facility
Trutnov, Czechia
Unknown Facility
Uherské Hradiště, Czechia
Unknown Facility
Ústí nad Labem, Czechia
Unknown Facility
Besançon, France
Unknown Facility
Brest, France
Unknown Facility
Colmar, France
Unknown Facility
Corbeil-Essonnes, France
Unknown Facility
Créteil, France
Unknown Facility
Grenoble, France
Unknown Facility
Lyon, France
Unknown Facility
Marseille, France
Unknown Facility
Metz, France
Unknown Facility
Nantes, France
Unknown Facility
Paris, France
Unknown Facility
Pierre-Bénit, France
Unknown Facility
Poitiers, France
Unknown Facility
Saint-Priest-en-Jarez, France
Unknown Facility
Strasbourg, France
Unknown Facility
Toulouse, France
Unknown Facility
Bad Kreuznach - Bosenheim, Germany
Unknown Facility
Cologne, Germany
Unknown Facility
Dietzenbach, Germany
Unknown Facility
Dresden, Germany
Unknown Facility
Essen, Germany
Unknown Facility
Hamburg, Germany
Unknown Facility
Hanover, Germany
Unknown Facility
Münster, Germany
Unknown Facility
Guatemala City, Guatemala
Unknown Facility
Baja, Hungary
Unknown Facility
Balatonfüred, Hungary
Unknown Facility
Budapest, Hungary
Unknown Facility
Debrecen, Hungary
Unknown Facility
Eger, Hungary
Unknown Facility
Esztergom, Hungary
Unknown Facility
Gödöllő, Hungary
Unknown Facility
Gyula, Hungary
Unknown Facility
Hu-4012 Debrecen N/a, Hungary
Unknown Facility
Kaposvár, Hungary
Unknown Facility
Kecskemét, Hungary
Unknown Facility
Komárom, Hungary
Unknown Facility
Nyíregyháza, Hungary
Unknown Facility
Pécs, Hungary
Unknown Facility
Szeged, Hungary
Unknown Facility
Szigetvár, Hungary
Unknown Facility
Veszprém, Hungary
Unknown Facility
Zalaegerszeg, Hungary
Unknown Facility
Calicut, India
Unknown Facility
Chennai, India
Unknown Facility
Delhi, India
Unknown Facility
Hyderabad, India
Unknown Facility
Kozhikode, India
Unknown Facility
Lucknow, India
Unknown Facility
Ludhiyāna, India
Unknown Facility
Mangalore, India
Unknown Facility
Mumbai, India
Unknown Facility
Mysore, India
Unknown Facility
Secunderabad, India
Unknown Facility
Trivandrum, India
Unknown Facility
Vijayawada, India
Unknown Facility
Visakhapatnam, India
Unknown Facility
Ageo-shi, Japan
Unknown Facility
Chiyoda-ku, Japan
Unknown Facility
Fukuoka, Japan
Unknown Facility
Hamamatsu, Japan
Unknown Facility
Hamura-shi, Japan
Unknown Facility
Ina-shi, Japan
Unknown Facility
Izumisano, Japan
Unknown Facility
Kamakura-shi, Japan
Unknown Facility
Kanazawa, Japan
Unknown Facility
Kawanishi-shi, Japan
Unknown Facility
Koriyama-shi, Japan
Unknown Facility
Kuki-shi, Japan
Unknown Facility
Kyoto, Japan
Unknown Facility
Matsuyama, Japan
Unknown Facility
Midori, Japan
Unknown Facility
Minatoku, Japan
Unknown Facility
Nagoya, Japan
Unknown Facility
Osaka, Japan
Unknown Facility
Ota-shi, Japan
Unknown Facility
Saiki-shi, Japan
Unknown Facility
Sashima-gun, Japan
Unknown Facility
Shinjuku-ku, Japan
Unknown Facility
Toyama, Japan
Unknown Facility
Uwajima-shi, Japan
Unknown Facility
Yamanashi, Japan
Unknown Facility
Yokohama, Japan
Unknown Facility
Kaunas, Lithuania
Unknown Facility
Klaipėda, Lithuania
Unknown Facility
Šiauliai, Lithuania
Unknown Facility
Batu Caves, Malaysia
Unknown Facility
Ipoh, Malaysia
Unknown Facility
Johor Bahru, Malaysia
Unknown Facility
Kuala Lumpur, Malaysia
Unknown Facility
Kuantan, Malaysia
Unknown Facility
Malacca, Malaysia
Unknown Facility
Perai, Malaysia
Unknown Facility
Petaling Jaya, Malaysia
Unknown Facility
Seremban, Malaysia
Unknown Facility
Seri Manjung, Malaysia
Unknown Facility
Sungai Petani, Kedah, Malaysia
Unknown Facility
Tampin, Malaysia
Unknown Facility
Temerluh, Malaysia
Unknown Facility
Aguascalientes, Mexico
Unknown Facility
Celaya, Mexico
Unknown Facility
Chihuahua City, Mexico
Unknown Facility
Ciudad de Mexic, Mexico
Unknown Facility
Cuautitlán Izcalli, Mexico
Unknown Facility
Culiacán, Mexico
Unknown Facility
Durango, Mexico
Unknown Facility
El Salto, Mexico
Unknown Facility
Guadalajara, Mexico
Unknown Facility
León, Mexico
Unknown Facility
Mexico City, Mexico
Unknown Facility
Mérida, Mexico
Unknown Facility
México, Mexico
Unknown Facility
Monterrey, Mexico
Unknown Facility
Morelia, Mexico
Unknown Facility
Orizaba, Mexico
Unknown Facility
Pachuca, Mexico
Unknown Facility
Querétaro, Mexico
Unknown Facility
San Luis Potosí City, Mexico
Unknown Facility
Tlalnepantla, Mexico
Unknown Facility
Veracruz, Mexico
Unknown Facility
Zapopan, Mexico
Unknown Facility
Auckland, New Zealand
Unknown Facility
Christchurch, New Zealand
Unknown Facility
Dunedin, New Zealand
Unknown Facility
Palmerston North, New Zealand
Unknown Facility
Rotorua, New Zealand
Unknown Facility
Takapuna Auckland, New Zealand
Unknown Facility
Tauranga, New Zealand
Unknown Facility
Wellington, New Zealand
Unknown Facility
Cagayan de Oro, Philippines
Unknown Facility
Cebu, Philippines
Unknown Facility
Cebuu City, Philippines
Unknown Facility
Davao City, Philippines
Unknown Facility
Iloilo City, Philippines
Unknown Facility
Lipa City, Philippines
Unknown Facility
Marikina City, Philippines
Unknown Facility
Pasay, Philippines
Unknown Facility
Pasig, Philippines
Unknown Facility
Quezon City, Philippines
Unknown Facility
San Fernando City, Philippines
Unknown Facility
Tagbilaran City, Philippines
Unknown Facility
Taytay, Philippines
Unknown Facility
Bydgoszcz, Poland
Unknown Facility
Chorzów, Poland
Unknown Facility
Katowice, Poland
Unknown Facility
Krakow, Poland
Unknown Facility
Lodz, Poland
Unknown Facility
Lublin, Poland
Unknown Facility
Parczew, Poland
Unknown Facility
Poznan, Poland
Unknown Facility
Radom, Poland
Unknown Facility
Rzeszów, Poland
Unknown Facility
Torun, Poland
Unknown Facility
Warswa, Poland
Unknown Facility
Wroclaw, Poland
Unknown Facility
Zgierz, Poland
Unknown Facility
Żnin, Poland
Unknown Facility
Caguas, Puerto Rico
Unknown Facility
Ponce, Puerto Rico
Unknown Facility
San Juan, Puerto Rico
Unknown Facility
Brasov, Romania
Unknown Facility
Bucharest, Romania
Unknown Facility
Cluj-Napoca, Romania
Unknown Facility
Deva, Romania
Unknown Facility
Iași, Romania
Unknown Facility
Oradea, Romania
Unknown Facility
Ploieşti, Romania
Unknown Facility
Târgu Mureş, Romania
Unknown Facility
Timișoara, Romania
Unknown Facility
Arkhangelsk, Russia
Unknown Facility
Barnaul, Russia
Unknown Facility
Ivanovo, Russia
Unknown Facility
Kemerovo, Russia
Unknown Facility
Moscow, Russia
Unknown Facility
Novosibirsk, Russia
Unknown Facility
Petrozavodsk, Russia
Unknown Facility
Rostov-on-Don, Russia
Unknown Facility
Ryazan, Russia
Unknown Facility
Saint Petersburg, Russia
Unknown Facility
Saratov, Russia
Unknown Facility
Sestroretsk, Saint-Petersburg, Russia
Unknown Facility
Tomsk, Russia
Unknown Facility
Ufa, Russia
Unknown Facility
Volgograd, Russia
Unknown Facility
Yaroslavl, Russia
Unknown Facility
Belgrade, Serbia
Unknown Facility
Niš, Serbia
Unknown Facility
Zaječar, Serbia
Unknown Facility
Bardejov, Slovakia
Unknown Facility
Bratislava, Slovakia
Unknown Facility
Košice, Slovakia
Unknown Facility
Ľubochňa, Slovakia
Unknown Facility
Nitra, Slovakia
Unknown Facility
Prievidza, Slovakia
Unknown Facility
Púchov, Slovakia
Unknown Facility
Rimavská Sobota, Slovakia
Unknown Facility
Svidník, Slovakia
Unknown Facility
Štúrovo, Slovakia
Unknown Facility
Žilina, Slovakia
Unknown Facility
Cape Town, South Africa
Unknown Facility
Durban, South Africa
Unknown Facility
Isipingo Rail, South Africa
Unknown Facility
Johannesburg, South Africa
Unknown Facility
Krugersdorp, South Africa
Unknown Facility
Port Elizabeth, South Africa
Unknown Facility
Pretoria, South Africa
Unknown Facility
Pretoria Gauteng, South Africa
Unknown Facility
Soweto, South Africa
Unknown Facility
Busan, South Korea
Unknown Facility
Daegu, South Korea
Unknown Facility
Incheon, South Korea
Unknown Facility
Seongnam, South Korea
Unknown Facility
Seoul, South Korea
Unknown Facility
A Coruña, Spain
Unknown Facility
Almería, Spain
Unknown Facility
Barcelona, Spain
Unknown Facility
Burela de Cabo, Spain
Unknown Facility
Ciudad Real, Spain
Unknown Facility
Getafe, Spain
Unknown Facility
Girona, Spain
Unknown Facility
Granada, Spain
Unknown Facility
La Roca del Vallès, Spain
Unknown Facility
Madrid, Spain
Unknown Facility
Majadahonda, Spain
Unknown Facility
Málaga, Spain
Unknown Facility
Palma de Mallorca, Spain
Unknown Facility
Pozuelo de Alarcón, Spain
Unknown Facility
Sagunto, Spain
Unknown Facility
Santander, Spain
Unknown Facility
Seville, Spain
Unknown Facility
Valencia, Spain
Unknown Facility
Vic, Spain
Unknown Facility
Viladecans, Spain
Unknown Facility
Kaohsiung City, Taiwan
Unknown Facility
New Taipei City, Taiwan
Unknown Facility
Taichung, Taiwan
Unknown Facility
Taipei, Taiwan
Unknown Facility
Chernivtsi, Ukraine
Unknown Facility
Dnipropetrovsk, Ukraine
Unknown Facility
Ivano-Frankivsk, Ukraine
Unknown Facility
Kharkiv, Ukraine
Unknown Facility
Kiev, Ukraine
Unknown Facility
Kyiv, Ukraine
Unknown Facility
Ternopil, Ukraine
Unknown Facility
Vinnitsya, Ukraine
Unknown Facility
Vinnytsia, Ukraine
Unknown Facility
Zaporizhzhia, Ukraine
Unknown Facility
Ajman, United Arab Emirates
Unknown Facility
Dubai, United Arab Emirates
Unknown Facility
Sharjah city, United Arab Emirates
Unknown Facility
Aberdeen, United Kingdom
Unknown Facility
Antrim, United Kingdom
Unknown Facility
Barry, United Kingdom
Unknown Facility
Birmingham, United Kingdom
Unknown Facility
Blackburn, United Kingdom
Unknown Facility
Bolton, United Kingdom
Unknown Facility
Bournemouth, United Kingdom
Unknown Facility
Bradford, United Kingdom
Unknown Facility
Bristol, United Kingdom
Unknown Facility
Burbage, United Kingdom
Unknown Facility
Cardff, United Kingdom
Unknown Facility
Cardiff, United Kingdom
Unknown Facility
Carlshalton, United Kingdom
Unknown Facility
Carmarthen, United Kingdom
Unknown Facility
Chester, United Kingdom
Unknown Facility
Darlington, United Kingdom
Unknown Facility
Doncaster, United Kingdom
Unknown Facility
Durham, United Kingdom
Unknown Facility
Ely, United Kingdom
Unknown Facility
Hampstead, United Kingdom
Unknown Facility
Harlow, United Kingdom
Unknown Facility
Huntingdon, United Kingdom
Unknown Facility
Liskeard, United Kingdom
Unknown Facility
London, United Kingdom
Unknown Facility
Middlesbrough, United Kingdom
Unknown Facility
Plymouth, United Kingdom
Unknown Facility
Rhyl, United Kingdom
Unknown Facility
Royal Leamington Spa, United Kingdom
Unknown Facility
Rugby, United Kingdom
Unknown Facility
Salford, United Kingdom
Unknown Facility
Stoke-on-Trent, United Kingdom
Unknown Facility
Swansea, United Kingdom
Unknown Facility
Torpoint, United Kingdom
Unknown Facility
Watford, United Kingdom
Unknown Facility
Welwyn Garden City, United Kingdom
Unknown Facility
Westcliff-on-Sea, United Kingdom
Unknown Facility
Wokingham, United Kingdom
Unknown Facility
Wolverhampton, United Kingdom
Related Publications (40)
Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2025 Nov 6. doi: 10.1681/ASN.0000000928. Online ahead of print. No abstract available.
PMID: 41196655DERIVEDBayes-Genis A, Cai A, Liu Y, Pandey A, Pop-Busui R, Hansen M, Januzzi JL. Impact of canagliflozin on heart stress and outcomes: Pooled insights from CREDENCE and CANVAS. Eur J Heart Fail. 2025 Dec;27(12):2887-2896. doi: 10.1002/ejhf.3786. Epub 2025 Jul 21.
PMID: 40689549DERIVEDOshima M, Buizen L, Jongs N, Levin A, Chertow GM, Wheeler DC, Heerspink HJL, Arnott C, Jardine MJ, Mahaffey KW, Pollock C, Herrington WG, Perkovic V, Neuen BL. Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials. Clin J Am Soc Nephrol. 2025 Jul 14;20(9):1206-1214. doi: 10.2215/CJN.0000000771.
PMID: 40658498DERIVEDJongs N, Gasparyan SB, Frison L, Schloemer P, Brinker M, Little DJ, Heerspink HJL. Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point. J Am Soc Nephrol. 2025 Dec 1;36(12):2421-2430. doi: 10.1681/ASN.0000000766. Epub 2025 Jun 17.
PMID: 40526444DERIVEDJanuzzi JLJ, Sattar N, Vaduganathan M, Magaret CA, Rhyne RF, Liu Y, Masson S, Butler J, Hansen MK. A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease. Cardiovasc Diabetol. 2025 May 15;24(1):213. doi: 10.1186/s12933-025-02779-5.
PMID: 40375260DERIVEDDoi Y, Hamano T, Yamaguchi O, Isaka Y. Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females. Blood Adv. 2025 Jul 8;9(13):3202-3212. doi: 10.1182/bloodadvances.2025016320.
PMID: 40239057DERIVEDNguyen TN, Yu J, Perkovic V, Jardine M, Mahaffey KW, Chow CK, Arnott C, Lindley RI. The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials. J Am Geriatr Soc. 2025 Jun;73(6):1787-1796. doi: 10.1111/jgs.19444. Epub 2025 Mar 19.
PMID: 40105285DERIVEDChatur S, Vaduganathan M, Fletcher RA, Perkovic V, Heerspink H, Arnott C, Pollock C, Mahaffey KW, Neal B, Jardine M, Solomon SD, Neuen BL. Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials. Eur J Heart Fail. 2025 Jun;27(6):994-1002. doi: 10.1002/ejhf.3586. Epub 2025 Jan 23.
PMID: 39844714DERIVEDVaduganathan M, Cannon CP, Jardine MJ, Heerspink HJL, Arnott C, Neuen BL, Sarraju A, Gogate J, Seufert J, Neal B, Perkovic V, Mahaffey KW, Kosiborod MN. Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial. Eur J Heart Fail. 2024 Sep;26(9):1967-1975. doi: 10.1002/ejhf.3292. Epub 2024 Jun 26.
PMID: 38932575DERIVEDNatale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
PMID: 38770818DERIVEDJanuzzi JL Jr, Liu Y, Sattar N, Yavin Y, Pollock CA, Butler J, Jardine M, Heerspink HJL, Masson S, Breyer M, Hansen MK. Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial. Am Heart J. 2024 May;271:38-47. doi: 10.1016/j.ahj.2024.02.016. Epub 2024 Feb 22.
PMID: 38401646DERIVEDSharma A, Razaghizad A, Joury A, Levin A, Bajaj HS, Mancini GBJ, Wong NC, Slee A, Ang FG, Rapattoni W, Neuen BL, Arnott C, Perkovic V, Mahaffey KW. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. J Am Heart Assoc. 2024 Feb 6;13(3):e031586. doi: 10.1161/JAHA.123.031586. Epub 2024 Jan 19.
PMID: 38240199DERIVEDMohebi R, Liu Y, Hansen MK, Yavin Y, Sattar N, Pollock CA, Butler J, Jardine M, Masson S, Heerspink HJL, Januzzi JL Jr. Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points. Clin J Am Soc Nephrol. 2024 Apr 1;19(4):429-437. doi: 10.2215/CJN.0000000000000389. Epub 2023 Dec 14.
PMID: 38099944DERIVEDFletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. J Am Soc Nephrol. 2023 Dec 1;34(12):1965-1975. doi: 10.1681/ASN.0000000000000248. Epub 2023 Oct 25.
PMID: 37876229DERIVEDHeerspink HJL, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, Karpefors M, Wheeler DC, Bakris G, Perkovic V, Nkulikiyinka R, Rossert J, Gasparyan SB. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023 Dec 1;34(12):2025-2038. doi: 10.1681/ASN.0000000000000243. Epub 2023 Oct 24.
PMID: 37872654DERIVEDYu J, Sweeting AN, Gianacas C, Houston L, Lee V, Fletcher RA, Perkovic V, Li Q, Neuen BL, Berwanger O, Heerspink HJL, de Zeeuw D, Arnott C. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2023 Dec;25(12):3724-3735. doi: 10.1111/dom.15267. Epub 2023 Sep 6.
PMID: 37671609DERIVEDJanuzzi JL, Mohebi R, Liu Y, Sattar N, Heerspink HJL, Tefera E, Vaduganathan M, Butler J, Yavin Y, Li J, Pollock CA, Perkovic V, Neal B, Hansen MK. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial. Circulation. 2023 Aug 22;148(8):651-660. doi: 10.1161/CIRCULATIONAHA.123.065251. Epub 2023 Aug 21.
PMID: 37603600DERIVEDMohebi R, Liu Y, Hansen MK, Yavin Y, Sattar N, Pollock CA, Butler J, Jardine M, Masson S, Heerspink HJL, Januzzi JL Jr. Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial. Cardiovasc Diabetol. 2023 Jul 12;22(1):176. doi: 10.1186/s12933-023-01916-2.
PMID: 37438734DERIVEDFletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJL, Jardine MJ, Mahaffey KW, Neal B, Pollock C, Jun M, Rodgers A, Perkovic V, Neuen BL. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 Jul 4;12(13):e028516. doi: 10.1161/JAHA.122.028516. Epub 2023 Jun 22.
PMID: 37345834DERIVEDFerrannini G, Pollock C, Natali A, Yavin Y, Mahaffey KW, Ferrannini E. Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE. Cardiovasc Diabetol. 2023 Apr 29;22(1):100. doi: 10.1186/s12933-023-01832-5.
PMID: 37120538DERIVEDvan der Hoek S, Jongs N, Oshima M, Neuen BL, Stevens J, Perkovic V, Levin A, Mahaffey KW, Pollock C, Greene T, Wheeler DC, Jardine MJ, Heerspink HJL. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):748-758. doi: 10.2215/CJN.0000000000000161. Epub 2023 Mar 31.
PMID: 36999981DERIVEDYi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M; CREDENCE Trial Investigators. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 Jul;82(1):84-96.e1. doi: 10.1053/j.ajkd.2022.12.015. Epub 2023 Mar 7.
PMID: 36889425DERIVEDSarraju A, Bakris G, Cannon CP, Cherney D, Damaraju CV, Figtree GA, Gogate J, Greene T, Heerspink HJL, Januzzi JL Jr, Neal B, Jardine MJ, Blais J, Kosiborod M, Levin A, Lingvay I, Weir MR, Perkovic V, Mahaffey KW. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 Nov 1;80(18):1721-1731. doi: 10.1016/j.jacc.2022.08.772.
PMID: 36302584DERIVEDNunes JC, Yu J, Arnott C, Jardine MJ, Perkovic V, Mahaffey KW. Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program. Diabetes Obes Metab. 2022 Dec;24(12):2459-2464. doi: 10.1111/dom.14832. Epub 2022 Aug 19. No abstract available.
PMID: 35938182DERIVEDLi JW, Arnott C, Heerspink HJL, MBiostat QL, Cannon CP, Wheeler DC, Charytan DM, Barraclough J, Figtree GA, Agarwal R, Bakris G, de Zeeuw D, Greene T, Levin A, Pollock C, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Neal B, Jardine MJ. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. J Am Heart Assoc. 2022 Aug 16;11(16):e025045. doi: 10.1161/JAHA.121.025045. Epub 2022 Aug 5.
PMID: 35929472DERIVEDCharytan DM, Yu J, Jardine MJ, Cannon CP, Agarwal R, Bakris G, Greene T, Levin A, Pollock C, Powe NR, Arnott C, Mahaffey KW; CREDENCE study investigators. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 Mar;17(3):361-373. doi: 10.2215/CJN.08980621. Epub 2022 Jan 21.
PMID: 35063969DERIVEDHeerspink HJL, Oshima M, Zhang H, Li J, Agarwal R, Capuano G, Charytan DM, Craig J, de Zeeuw D, Di Tanna GL, Levin A, Neal B, Perkovic V, Wheeler DC, Yavin Y, Jardine MJ. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. Am J Kidney Dis. 2022 Feb;79(2):244-256.e1. doi: 10.1053/j.ajkd.2021.05.005. Epub 2021 May 23.
PMID: 34029680DERIVEDZhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, Neal B, Lindley RI; CREDENCE Trial Investigators*. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. Stroke. 2021 May;52(5):1545-1556. doi: 10.1161/STROKEAHA.120.031623. Epub 2021 Apr 20.
PMID: 33874750DERIVEDYu J, Li J, Leaver PJ, Arnott C, Huffman MD, Udell JA, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Rosenthal N, Neal B, Figtree GA. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. Cardiovasc Res. 2022 Mar 16;118(4):1103-1114. doi: 10.1093/cvr/cvab128.
PMID: 33826709DERIVEDJardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R, Bakris GL, Cannon CP, Charytan DM, Greene T, Levin A, Li JW, Neuen BL, Neal B, Oh R, Oshima M, Pollock C, Wheeler DC, de Zeeuw D, Zhang H, Zinman B, Mahaffey KW, Perkovic V. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 Mar 8;16(3):384-395. doi: 10.2215/CJN.15260920. Epub 2021 Feb 22.
PMID: 33619120DERIVEDYe N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, Bakris G, Schutte AE, Arnott C, Chang TI, Gorriz JL, Cannon CP, Charytan DM, de Zeeuw D, Levin A, Mahaffey KW, Neal B, Pollock C, Wheeler DC, Luca Di Tanna G, Cheng H, Perkovic V, Neuen BL. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Circulation. 2021 May 4;143(18):1735-1749. doi: 10.1161/CIRCULATIONAHA.120.048740. Epub 2021 Feb 8.
PMID: 33554616DERIVEDSarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 Mar;233:141-148. doi: 10.1016/j.ahj.2020.12.008. Epub 2020 Dec 22.
PMID: 33358942DERIVEDDurkin M, Blais J. Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy. Diabetes Ther. 2021 Feb;12(2):499-508. doi: 10.1007/s13300-020-00953-4. Epub 2020 Dec 18.
PMID: 33340064DERIVEDWillis M, Nilsson A, Kellerborg K, Ball P, Roe R, Traina S, Beale R, Newell I. Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model. Diabetes Ther. 2021 Jan;12(1):313-328. doi: 10.1007/s13300-020-00968-x. Epub 2020 Dec 2.
PMID: 33263893DERIVEDWillis M, Asseburg C, Slee A, Nilsson A, Neslusan C. Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data. Diabetes Ther. 2020 Nov;11(11):2657-2676. doi: 10.1007/s13300-020-00923-w. Epub 2020 Sep 15.
PMID: 32930969DERIVEDJardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V; CREDENCE Study Investigators. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168.
PMID: 32354987DERIVEDCannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11. No abstract available.
PMID: 31707795DERIVEDMahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.
PMID: 31291786DERIVEDPerkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
PMID: 30990260DERIVEDJardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. Online ahead of print.
PMID: 29253846DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Senior Director
- Organization
- Janssen Research & Development, LLC
Study Officials
- STUDY DIRECTOR
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 17, 2014
First Posted
February 19, 2014
Study Start
February 17, 2014
Primary Completion
October 30, 2018
Study Completion
October 30, 2018
Last Updated
December 5, 2019
Results First Posted
November 20, 2019
Record last verified: 2019-12